The Medicines and Healthcare products Regulatory Agency (MHRA) has implemented updated UK clinical trial regulation amendments effective 28 April 2026. The revised framework introduces streamlined approval processes, enhanced safety oversight, improved transparency measures, and stronger sponsor accountability requirements. The amendments also reinforce expectations around GCP compliance, inspection readiness, documentation management, and trial governance. Sponsors and clinical organizations conducting trials in the UK are required to align operational and compliance processes with the updated regulatory expectations.
Select Mandate HA
Select Mandate Function